In the late 1970's the options for treatment ofoesophageal cancer were limited. When cure was thought possible, resection was performed by the Ivor Lewis or oesophagogastrectomy techniques. Mortality was high, local recurrence rates disappointing, and long-term survival poor. For those patients whose tumours could not be resected, palliative intubation required open operation with high morbidity, and gave poor quality oflife. In 1994, selective screening is diagnosing cancers early, more extensive resections are possible with lower mortality, and fewer local recurrences. Adjuvant therapy is increasing the operability rates. Gradually the facade of poor prognosis is being etched away, so that more patients are being given better quality of life, and cure is a distinct possibility. Palliation can be achieved endoscopically by dilatation, intubation or laser ablation combined with local external beam radiation. Mortality for palliative procedures is now considerably reduced.
INTRODUCTION
In 1987 a review of the treatment of oesophageal cancer over the preceding ten years was undertaken at the Royal Victoria Hospital. Of the 401 patients presenting to the hospital, exploratory surgery was performed on 247, and 221 underwent resection. Clear tumour margins were obtained in 112, 82 of whom survived their surgery. Thus only 20 per cent of those who presented for oesophageal surgery left hospital with their disease completely resected. The five-year survival following resection was 13.2% ( Fig. 1) . A broad range of factors affecting survival following resection have been examined, and while many were found to be significant, the only independent predictors of survival were sex, involvement of proximal resection margins, curative resection and presence of nodal metastases By way of palliation, 113 Celestin tubes were passed at open laparotomy or thoracotomy and 26 Atkinson tubes introduced endoscopically. In nine patients the tumours were bypassed, 21 patients were referred for primary radiotherapy, and 14 were unfit for surgical intervention. Following a transition period in 1986-1987, a number of changes have been made in the approach to oesophageal malignancies. Endoscopic surveillance has been introduced for patients with premalignant pathology. Laser ablation has become the treatment of choice for palliating inoperable tumours. For those in whom cure is thought possible, the more extensive total thoracic oesophagectomy operation has been introduced with the aim of resecting more of the proximal oesophagus, performing the anastomosis in the neck. Of the 139 oesophageal resections performed between 1988 and 1992, 73 have involved total oesophagectomy; 20 have been for benign or premalignant disease. In this paper we describe the changes in our approach to oesophageal cancer, the results of these changes, and outline future plans for treating this difficult disease. DIAGNOSIS AND SURVEILLANCE OF OESOPHAGEAL PREMALIGNANT CONDITIONS It has become apparent that peptic disorders are associated with oesophageal cancer. In the 1977-86 series, 21.5% of patients had hiatal hernia, and a further 24.3% had other peptic disease. In particular, patients whose oesophagitis has advanced to the stage where the oesophageal lining has changed to columnar intestinal epithelium (Barrett's metaplasia), have a cancer risk 40 times that of the normal population.' In conjunction with our colleagues in gastro-enterology, it is our practice to maintain endoscopic surveillance for all patients with Barrett's metaplasia. When 
RESECTIONS FOR OESOPHAGEAL CANCER
The standard oesophagogastrectomy procedure is usually performed via a left thoraco-abdominal incision (Fig 2) . The proximal limit of resection is judged by the surgeon to be a point 5-7 cm proximal to the palpable tumour. The anastomosis is made below the aortic arch within the chest. When the tumour encroaches significantly onto the stomach the resection is extended to include a total gastrectomy. The Ivor Lewis oesophagogastrectomy devised for more proximal tumours, requires an upper midline laparotomy for mobilization of the stomach and a right thoracotomy to resect the tumour, again with a 7 cm margin, the anastomosis being above the level of the azygos vein. The decision as to whether the oesophagogastrectomy or Ivor Lewis approach was used depended on the barium and endoscopic findings. Total thoracic oesophagectomy is performed using the technique described by Matthews2 using a left thoraco-abdominal incision, resembling that for the oesophago-gastrectomy but with further dissection of the oesophagus above the aortic arch into the neck from below. The anastomosis is performed via a small cervical incision. This operation is performed whenever there is enough stomach available after adequate tumourresection to reach comfortably to the neck. It is therefore not used for true gastric fundal tumours where an oesophago-gastrectomy or total gastrectomy is performed. The decision on the extent of resection does not need to be made until the tumour is mobilised and is fully assessible. Mention must be made of the 'transhiatal' oesophagectomy approach which is performed via a laparotomy with blunt dissection of the oesophageal tumour and anastomosis in the neck. This operation does fulfill the requirements of total thoracic oesophageal resection with the reduced morbidity of the cervical anastomosis but avoiding some of the complications of thoracotomy. While With the introduction of total thoracic oesophagectomy the incidence of proximal limit involvement and anastomotic recurrence has dropped to zero. Despite attempts to gain a greater proximal margin in both Ivor Lewis and oesophagogastrectomy resections, the recurrence rates remain high for these operations (38.5% for Ivor Lewis, 15.8% for oesophagogastrectomy). The distal clearance is similar between all groups though a number of tumours have recurred on the lesser curve of the stomach. The short and medium term survival in the total thoracic oesophagectomy group reflects the improvement in proximal tumour clearance (Fig. 5) . PALLIATION OF UNRESECTABLE OESOPHAGEAL CANCER Thirty eight per cent of oesophageal cancers present to this hospital in an inoperable state. Palliation, therefore, is a major part of the treatment of oesophageal cancer. Inability to swallow ones' own saliva is such an unpleasant end, that aggressive measures are usual'ly employed to restore at least a liquid diet, despite the considerable risks of some of the procedures.
Resection is a major debilitating operation with high risk and prolonged recovery. It is not indicated when metastatic disease is detected during preoperative staging or open exploration, nor when resection is likely to be incomplete and the prognosis poor. Tumour bypass is advocated by some authorities, especially in the case oftracheo-oesophageal fistula. 
